A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

Completed · Phase 3

Conditions studied: Diabetes Mellitus, Type 2

In brief

This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.

Key facts

Study ID

NCT00351507

Run by

Novartis Pharmaceuticals

People needed

10

Starts

2005-05-01

Expected to finish

2006-02-01

Last updated by the study team

2012-05-07

Who can join

Age: 35 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with type 2 diabetes for at least 6 months
• Blood glucose criteria must be met
• BMI in the range 22-40

You may not qualify if…

• History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
• Use of thiazolidinediones or need for insulin within 3 months prior to screening
• Significant concomitant diseases or complications of diabetes
• High fasting triglycerides as defined by the protocol
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.